Patient characteristics, response, and treatment results in age subgroups of (A) precursor B-cell (p-Bc) acute lymphoblastic leukemia (ALL) and (B) T cell ALL.*
| . | . | Age (years) . | . | ||
|---|---|---|---|---|---|
| Feature . | < 1 . | 1–5 . | 6–9 . | 10–14 . | 15–18 . |
| * Combined data from trials ALL-BFM 86 (n = 998) and ALL-BFM 90 (n = 2178); data are given in %. In 100 patients (3.1%) the immunophenotype was not available. | |||||
| PRED-PR: Prednisone poor-response, defined by ≥ 1000 leukemic blasts in peripheral blood after 7 days of prednisone and one dose of intrathecal methotrexate on day 1.12,80 In T cell ALL, only 3 patients were < 1 year old; therefore, data are not listed. | |||||
| CR: complete remission in the bone marrow (less than 5% blasts) after 6 weeks of induction therapy; no CR: no remission achieved, died due to disease. | |||||
| Abbreviations: CNS, central nervous system; pEFS, probability for event-free survival | |||||
| A. p-Bc ALL | |||||
| Total no. of patients | 90 | 1709 | 464 | 318 | 89 |
| Male | 50 | 54.6 | 52.4 | 54.7 | 53.9 |
| WBC (per μL) | |||||
| < 10,000 | 12.2 | 49.7 | 60.8 | 54.4 | 46.1 |
| 10–19,999 | 7.8 | 18.4 | 11.4 | 15.4 | 13.5 |
| 20–99,999 | 21.1 | 25.4 | 21.3 | 21.1 | 31.5 |
| ≥ 100,000 | 58.9 | 6.5 | 6.4 | 9.2 | 9.0 |
| CNS involvement | 11.1 | 1.4 | 0.4 | 1.3 | 4.5 |
| t(9;22) | – | 1.3 | 4.9 | 5.5 | 4.1 |
| PRED PR | 24.4 | 4.3 | 6.0 | 9.4 | 7.9 |
| Early death | 2.2 | 0.6 | 0.4 | 1.6 | 5.6 |
| No CR | 3.3 | 0.1 | 0.2 | 1.3 | 1.1 |
| Relapse | 45.6 | 15.8 | 25.4 | 29.9 | 28.1 |
| Death in CR | 2.2 | 1.1 | 1.3 | 3.8 | 0 |
| 10y-pEFS (SE) | 46.3 (5.3) | 80.4 (1.0) | 70.8 (2.2) | 60.6 (2.9) | 63.7 (5.3) |
| B. T Cell ALL | |||||
| Total no. of patients | 117 | 132 | 122 | 32 | |
| Male | 71.8 | 69.7 | 77.9 | 90.6 | |
| WBC (per μL) | |||||
| < 10,000 | 7.7 | 14.4 | 17.2 | 12.5 | |
| 10–19,999 | 6.8 | 12.9 | 9.0 | 3.1 | |
| 20–99,999 | 38.5 | 40.2 | 36.9 | 50 | |
| ≥ 100,000 | 47.0 | 32.6 | 36.9 | 34.4 | |
| CNS involvement | 10.3 | 9.1 | 7.4 | 12.5 | |
| PRED-PR | 32.5 | 29.5 | 32.0 | 40.6 | |
| Early death | 2.6 | 1.5 | – | – | |
| No CR | 2.6 | 2.3 | 2.5 | 3.1 | |
| Relapse | 22.2 | 26.5 | 31.1 | 37.5 | |
| Death in CR | 6.8 | 1.5 | 0 | 0 | |
| 10y-pEFS (SE) | 58.3 (4.8) | 66.1 (4.2) | 63.9 (4.5) | 58.5 (8.8) | |
| . | . | Age (years) . | . | ||
|---|---|---|---|---|---|
| Feature . | < 1 . | 1–5 . | 6–9 . | 10–14 . | 15–18 . |
| * Combined data from trials ALL-BFM 86 (n = 998) and ALL-BFM 90 (n = 2178); data are given in %. In 100 patients (3.1%) the immunophenotype was not available. | |||||
| PRED-PR: Prednisone poor-response, defined by ≥ 1000 leukemic blasts in peripheral blood after 7 days of prednisone and one dose of intrathecal methotrexate on day 1.12,80 In T cell ALL, only 3 patients were < 1 year old; therefore, data are not listed. | |||||
| CR: complete remission in the bone marrow (less than 5% blasts) after 6 weeks of induction therapy; no CR: no remission achieved, died due to disease. | |||||
| Abbreviations: CNS, central nervous system; pEFS, probability for event-free survival | |||||
| A. p-Bc ALL | |||||
| Total no. of patients | 90 | 1709 | 464 | 318 | 89 |
| Male | 50 | 54.6 | 52.4 | 54.7 | 53.9 |
| WBC (per μL) | |||||
| < 10,000 | 12.2 | 49.7 | 60.8 | 54.4 | 46.1 |
| 10–19,999 | 7.8 | 18.4 | 11.4 | 15.4 | 13.5 |
| 20–99,999 | 21.1 | 25.4 | 21.3 | 21.1 | 31.5 |
| ≥ 100,000 | 58.9 | 6.5 | 6.4 | 9.2 | 9.0 |
| CNS involvement | 11.1 | 1.4 | 0.4 | 1.3 | 4.5 |
| t(9;22) | – | 1.3 | 4.9 | 5.5 | 4.1 |
| PRED PR | 24.4 | 4.3 | 6.0 | 9.4 | 7.9 |
| Early death | 2.2 | 0.6 | 0.4 | 1.6 | 5.6 |
| No CR | 3.3 | 0.1 | 0.2 | 1.3 | 1.1 |
| Relapse | 45.6 | 15.8 | 25.4 | 29.9 | 28.1 |
| Death in CR | 2.2 | 1.1 | 1.3 | 3.8 | 0 |
| 10y-pEFS (SE) | 46.3 (5.3) | 80.4 (1.0) | 70.8 (2.2) | 60.6 (2.9) | 63.7 (5.3) |
| B. T Cell ALL | |||||
| Total no. of patients | 117 | 132 | 122 | 32 | |
| Male | 71.8 | 69.7 | 77.9 | 90.6 | |
| WBC (per μL) | |||||
| < 10,000 | 7.7 | 14.4 | 17.2 | 12.5 | |
| 10–19,999 | 6.8 | 12.9 | 9.0 | 3.1 | |
| 20–99,999 | 38.5 | 40.2 | 36.9 | 50 | |
| ≥ 100,000 | 47.0 | 32.6 | 36.9 | 34.4 | |
| CNS involvement | 10.3 | 9.1 | 7.4 | 12.5 | |
| PRED-PR | 32.5 | 29.5 | 32.0 | 40.6 | |
| Early death | 2.6 | 1.5 | – | – | |
| No CR | 2.6 | 2.3 | 2.5 | 3.1 | |
| Relapse | 22.2 | 26.5 | 31.1 | 37.5 | |
| Death in CR | 6.8 | 1.5 | 0 | 0 | |
| 10y-pEFS (SE) | 58.3 (4.8) | 66.1 (4.2) | 63.9 (4.5) | 58.5 (8.8) | |